Having "already achieved important milestones" in a first deal with Gubra ApS signed less than two years ago, Boehringer Ingelheim GmbH has entered into a second obesity collaboration with the Danish biotech.
The partners are teaming up again to develop poly-agonist peptides to treat obesity and concomitant diseases, saying that the collaboration...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?